Page 53 - BPOM Terbitkan EUA Vaksin Indovac dan Vaksin AWcorna
P. 53
and above.
IndoVac vaccine is targeted to be used for primary series, with the doses administered 28
days apart.
Regarding the IndoVac vaccine's efficacy, based on the results of the immuno-bridging study
in the phase three clinical trials, the vaccine's neutralizing antibodies are not inferior as
compared to the protein subunit vaccine that is used for comparison (92.5 percent vs 87.09
percent).
The reported side effects or adverse events in the clinical trials of the IndoVac vaccine are
mild. The vaccine has also received a halal certificate from the relevant authority in Indonesia.
“The most frequently reported side effects were local pain and muscle pain (myalgia) whose
occurrence was comparable to the side effects of using the comparison subunit protein
recombinant vaccine, which had already received EUA," she remarked.
